Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma

Table 1

Correlation of SNORA52 and clinical characteristics in HCC patients.

Characteristics	Total	SNORA52 expression		value
		Low ()	High ()
Age (ys)				0.607
<60	92	44 (0.611)	48 (0.658)
≥60	53	28 (0.389)	25 (0.342)
Gender				0.138
Female	19	6 (0.083)	13 (0.178)
Male	126	66 (0.917)	60 (0.822)
Hepatitis B				0.810
Positive	125	63 (0.875)	62 (0.849)
Negative	20	9 (0.125)	11 (0.151)
Cirrhosis				1.000
Present	89	44 (0.611)	45 (0.616)
Absent	56	28 (0.389)	28 (0.384)
AFP (ng/l)				0.230
<400	92	42 (0.583)	50 (0.685)
≥400	53	30 (0.417)	23 (0.315)
Tumor diameter				0.011
<5 cm	43	14 (0.194)	29 (0.397)
≥5 cm	102	58 (0.806)	44 (0.603)
Multiple lesions				0.007
Absent	24	18 (0.250)	6 (0.082)
Present	121	54 (0.750)	67 (0.918)
Vessel carcinoma embolus				0.127
Absent	109	50 (0.694)	59 (0.808)
Present	36	22 (0.306)	14 (0.192)
Microvascular invasion				1.000
Absent	136	68 (0.944)	68 (0.932)
Present	9	4 (0.056)	5 (0.068)
Capsular invasion				0.011
Absent	88	36 (0.500)	52 (0.712)
Present	57	36 (0.500)	21 (0.288)
Differentiation				0.046
Low	76	44 (0.377)	32 (0.438)
High/moderate	69	28 (0.389)	41 (0.562)
TNM stage				0.004
I~II	101	42 (0.583)	59 (0.808)
III~IV	44	30 (0.417)	14 (0.192)

AFP: α-fetoprotein; TNM: tumor-node-metastasis; . Values are presented as the or (%).